Detalhe da pesquisa
1.
Medical Costs of Respiratory Syncytial Virus-Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5 Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019.
J Pediatr
; 271: 114045, 2024 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38561048
2.
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
MMWR Morb Mortal Wkly Rep
; 73(9): 209-214, 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38457312
3.
Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States.
MMWR Morb Mortal Wkly Rep
; 73(8): 168-174, 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38421935
4.
SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months-4 Years - New Vaccine Surveillance Network, United States, July 2022-September 2023.
MMWR Morb Mortal Wkly Rep
; 72(48): 1300-1306, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38032834
5.
Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018-2024.
MMWR Morb Mortal Wkly Rep
; 73(7): 149-151, 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38386615
6.
A Methodology for Classifying Root Causes of Outbreaks of Legionnaires' Disease: Deficiencies in Environmental Control and Water Management.
Microorganisms
; 9(1)2021 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33401429